Worldwide emergence of extensively drug-resistant tuberculosis

Emerging Infectious Diseases

Volumn 13, Issue 3, 2007, Pages 380-387

  Shah, N Sarita ^a,p   Wright, Abigail ^b   Bai, Gill Han ^b,c   Barrera, Lucia ^b,d   Boulahbal, Fadila ^b,e   Martín Casabona, Nuria ^b,f   Drobniewski, Francis ^b,g   Gilpin, Chris ^b,h   Havelková, Marta ^b,i   Lepe, Rosario ^b,j   Lumb, Richard ^b,k   Metchock, Beverly ^a,b   Portaels, Françoise ^l   Rodrigues, Maria Filomena ^b,m   Rüsch Gerdes, Sabine ^b,n   Van Deun, Armand ^b,l   Vincent, Veronique ^b,o   Laserson, Kayla ^a   Wells, Charles ^a   Cegielski, J Peter ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Korean Institute of Tuberculosis   (South Korea)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Argentina)

^e Institut Pasteur d'Algerie   (Algeria)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

^h THE PRINCE CHARLES HOSPITAL   (Australia)

ⁱ NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^j Institute of Public Health of Chile   (Chile)

^k INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^l INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^m NATIONAL INSTITUTE OF HEALTH   (Portugal)

ⁿ German National Reference Center for Mycobacteria   (Germany)

^o INSTITUT PASTEUR   (France)

^p ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RIFAMPICIN; SALICYLIC ACID DERIVATIVE; STREPTOMYCIN; TERIZIDONE; THIOAMIDE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; DRUG SCREENING; DRUG SENSITIVITY; HEALTH PROGRAM; HUMAN; INCIDENCE; INFECTION CONTROL; KOREA; MULTIDRUG RESISTANCE; POPULATION RESEARCH; PRACTICE GUIDELINE; QUALITY CONTROL; TUBERCULOSIS;

EID: 33847414693     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1303.061400     Document Type: Article

References (32)

1. World Health Organization. Anti-tuberculosis drug resistance in the world: Report 3. Document no. (WHO/HTM/TB/2004.343). Geneva: The Organization; 2004.
2. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006;194:479-85.
3. Rajbhandary SS, Marks SM, Bock NN. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8:1012-6.
4. Ward HA, Marciniuk DD, Hoeppner VH, Jones W. Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants. Int J Tuberc Lung Dis. 2005;9:164-9.
5. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blondal K, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis. 2006;12:1389-97.
6. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329:784-91.
7. Pablos-Mendez A, Lessnau K. Clinical mismanagement and other factors producing antituberculosis drug resistance. In: Bastian I, Portaels F, editors. Multidrug-resistant tuberculosis. Dordrecht (the Netherlands): Kluwer Academic Publishers; 2000. p. 59-76.
8. Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-Van Weezenbeek CS, et al. Increasing transparency in partnerships for health: introducing the Green Light Committee. Trop Med Int Health. 2002;7:970-6.
9. Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, Nivin B, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis. JAMA. 1996;276:1229-35.
10. Coronado VG, Beck-Sague CM, Hutton MD, Davis BJ, Nicholas P, Villareal C, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis. 1993;168:1052-5.
11. Breathnach AS, de Ruiter A, Holdsworth GM, Bateman NT, O'Sullivan DG, Rees PJ, et al. An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital. J Hosp Infect. 1998;39:111-7.
12. Centers for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons - Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep. 1991;40:585-91.
13. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326:1514-21.
14. Laszlo A, Rahman M, Espinal M, Raviglione M; WHO/IUATLD Network of Supranational Reference Laboratories. Quality assurance program for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis. 2002;6:748-56.
15. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis [cited 2006 Jan 5]. Geneva: The Organization; 2006. Document no. WHO/HTM/TB/2006.361. Available from http://whqlibdoc.who.int/ publications/2006/9241546956_eng.pdf
16. World Health Organization. Global tuberculosis control: WHO report. Geneva: The Organization; 2006. Document no. WHO/HTM/TB/2006.362.
17. Kam KM, Yip CW. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-Plus. Int J Tuberc Lung Dis. 2004;8:760-6.
18. Pardini M, Iona E, Varaine F, Karakozian H, Arzumanian H, Brunori L, et al. Mycobacterium tuberculosis drug resistance: Abkhazia [letter]. Emerg Infect Dis. 2005;11:501-3.
19. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death among patient co-infected with tuberculosis and HIV in a rural area in South Africa. Lancet. 2006;368:1575-80.
20. Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis. 2006;43:841-7.
21. Lambregts-van Weezenbeek KSB, Reichman LB. DOTS and DOTS-Plus: what's in a name. Int J Tuberc Lung Dis. 2000;4:995-6. 22. Kim SJ. Is second-line anti-tuberculosis drug susceptibility testing reliable? [letter]. Int J Tuberc Lung Dis. 2004;8:1157-8.
22. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis. 1999;3:564-81.
23. Krüüner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol. 2006;44:811-8.
24. Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of drug susceptibility testing of Mycobacterium tuberculosis against classical second-line drugs and newer antimicrobials by the BACTEC MGIT 960 technique. J Clin Microbiol. 2006;44:688-92.
25. Pfyffer GE, Bonato DA, Ebrahimzadeh A, Gross W, Hotaling J, Kornblum J, et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical secondline and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol. 1999;37:3179-86.
26. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis. 1965;92:687-703.
27. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2005;49:3192-7.
28. McClatchy JK, Kanes W, Davidson PT, Moulding TS. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. Tubercle. 1977;58:29-34.
29. Centers for Disease Control and Prevention. Outbreak of multidrug-resistant tuberculosis at a hospital - New York City, 1991. MMWR Morb Mortal Wkly Rep. 1993;42:427-33.
30. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to secondline drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-5.
31. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365:318-26.
32. Tuberculosis Coalition for Technical Assistance. International standards for tuberculosis care [cited 2006 Jan 5]. The Hague: The Coalition; 2006. Available from http://www.who.int/tb/publications/2006/istc_report.pdf